|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-1.45/2.85
|
Enterprise Value
35.78B
|
Balance Sheet |
Book Value Per Share
4.69
|
Cash Flow |
Cash Flow Yield
0.06
|
Income Statement |
Total Revenue
16.54B
|
Operating Revenue Per Share
13.11
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor. |